Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma
Conditions
Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Mixed Cellularity Classical Hodgkin Lymphoma, Nodular Sclerosis Classical Hodgkin Lymphoma
Trial Timeline
Nov 9, 2017 → Oct 1, 2024
NCT ID
NCT03226249About Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate
Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate is a phase 2 stage product being developed by Merck for Classical Hodgkin Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03226249. Target conditions include Classical Hodgkin Lymphoma, Lymphocyte-Depleted Classical Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03226249 | Phase 2 | UNKNOWN |
Competing Products
11 competing products in Classical Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 52 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 52 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| PD1 | Innovent Biologics | Phase 2 | 51 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 32 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 74 |
| GEN3017 | Genmab | Phase 1/2 | 38 |